secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001104659-25-030583
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara stockholders approve all six merger proposals with Tvardi; Tvardi posts $29.4M net loss
--------------------------------------------------------------------------------

- All proposals passed: stock issuance for merger (2,088,293 for), equity plan, ESPP, reverse split (1:2-1:4), authorized shares increase to 150M, and advisory compensation.
- Reverse stock split ratio between 1-for-2 and 1-for-4 to be mutually agreed by Cara and Tvardi boards before merger.
- Tvardi audited 2024: net loss $29.4M (vs $17.3M in 2023), cash $31.6M, with going concern qualification.
- Tvardi's lead candidate TTI-101 in Phase 2 for idiopathic pulmonary fibrosis and hepatocellular carcinoma.
- Merger completion subject to customary closing conditions including Cara net cash of at least $18M at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925030583/0001104659-25-030583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925030583/tm2510381d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-030583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer